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Intercellular adhesion molecule-1 (ICAM-1, CD54), a member of
the immunoglobulin superfamily (Staunton et al, 1988), acts as a
counter-receptor for leucocyte function associated antigen-1
(LFA-1, CD11a/CD18) (Marlin and Springer, 1987) present on the
surface of T-lymphocytes, lymphokine-activated killer (LAK)
cells and natural killer cells. Melanoma cells are among the
various cell types known to express membrane ICAM-1 (mICAM-
1), which may be crucial for the interaction with the immune
system. mICAM-1 levels are induced by cytokines such as inter-
feron g (IFN-g), tumour necrosis factor a (TNF-a) and interleukin-
1 (IL-1) (Rothlein et al, 1988) which are reported to make the
tumour cells more susceptible to lysis by cells of the immune
system (Webb et al, 1991). One possible mechanism as to how
tumour cells evade immunosurveillance by lymphocytes is
through the release of a soluble form of ICAM-1 (sICAM-1)
which may exist as a multimeric form or complexed with other
proteins, and is of lower molecular mass (80 kDa) (Rothlein et al,
1991) than membrane ICAM-1 (90 kDa) (Marlin and Springer,
1987). Serum levels have been reported to increase in various
disease states (Banks et al, 1993) which include human malignant
melanoma (Harning et al, 1991); however, the biological conse-
quences of such increases remains controversial. It is possible that
binding of sICAM-1 to the LFA-1 receptor could prevent the
lymphocyte from interacting with mICAM-1 and thus prevent
tumour cell lysis occurring. This is supported by reports from
various groups (Becker et al, 1992; Altomonte et al, 1993) but
which is in contrast to the recent data from Young et al (1997) who
reported on the inability of sICAM-1 to affect tumour cell lysis.
The biologically active derivative of vitamin A, retinoic acid
(RA), is known to have effects on tumour growth, differentiation,
adhesive properties and apoptosis. It has been used in cancer
therapy and is thought to render many tumour cells more suscep-
tible to attack by effector cells of the immune system (Smith et al,
1992). The retinoids exert their physiological actions by binding to
nuclear receptors which dimerize and interact with specific sites
on the DNA termed the RA response elements (RARE). The
promoter region of the gene for ICAM-1 has been shown to
contain a RARE (Aoudjit et al, 1994), suggesting RA has the
ability to alter ICAM-1 expression (Cilenti et al, 1995). RA is
known to increase ICAM-1 expression in several cell types
including melanoma cells (Bouillon et al, 1991), mast cells
(Babina et al, 1997) and epithelial cells (Gao and Mackenzie,
1996). In this study, we investigate the effect of RA on its ability to
alter both membrane and soluble ICAM-1 expression and the
immunological consequences of such treatments in vitro. We
compare the highly metastatic C8161 human melanoma cell line
with the low metastatic Hs294T cell line, focusing on modulation
of the interaction between untreated/treated tumour cells and
LAK cells.
MATERIALS AND METHODS
Materials
Eagle’s minimal essential medium (EMEM), Dulbecco’s modified
Eagle medium (DMEM), RPMI-1640, phosphate-buffered saline
(PBS), fetal calf serum (FCS), penicillin–streptomycin, L-gluta-
mine, trypsin and Nunclon tissue culture plastics were obtained
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from Life Technologies Ltd (Paisley, UK). All-trans RA was
purchased from Sigma Chemical Co (Dorset, UK) while Ficoll-
hypaque research grade was from Pharmacia Biotech,
(Hertfordshire, UK). Chromium-51 was obtained from Amersham
International plc (Buckinghamshire, UK). Human recombinant
interleukin-2 (h-rIL2), recombinant sICAM-1, fluorescein isothio-
cyanate (FITC)-conjugated anti-human ICAM-1 antibody and the
monoclonal mouse anti-human ICAM-1 blocking antibody were
from R&D Systems Europe (Abingdon, UK). The non-specific
mouse IgG control antibody was from the Scottish Antibody
Production Unit (SAPU, Law Hospital, UK). Mouse anti-human
HLA–ABC antibody was purchased from Serotec Ltd (Oxford,
UK).
Cell culture
The highly metastatic human melanoma C8161 cell line was
established from an abdominal wall metastasis and characterized
by Welch et al (1991) and was kindly supplied by Mary JC
Hendrix (University of Arizona, Tucson, AZ, USA). The low
metastatic Hs294T cell line (Creasey et al, 1979), derived from a
lung node metastasis, was obtained from the American Tissue
Culture Collection (ATCC, HTB-140). Both cell lines were
routinely cultured in EMEM supplemented with 10% heat-
inactivated FCS, penicillin (100 units ml–1) and streptomycin
(100 mg ml–1). Cells were maintained in a humidified atmosphere
of 5% carbon dioxide in air at 37°C.
Methods
Preparation of lymphocytes
Eighty millilitres of heparinized blood from a healthy volunteer
were subjected to Ficoll density gradient centrifugation and the
peripheral blood mononuclear cell layer removed. Adherent cells
were removed by two cycles of adherence to tissue culture plastic.
The non-adherent peripheral blood lymphocytes (PBL) were
collected and maintained in RPMI supplemented with 10% FCS
and lymphocytes activated by the addition of 2 nM h-rIL2 to 106
cells for at least 6 days to produce LAK cells.
Assessment of PBL and LAK cell-mediated tumour cell
lysis
Chromium-51 release assay
A total of 5 ´ 103 tumour cells, either untreated or treated with
10–10 M to 10-6 M RA for 4 days, were radiolabelled with
Chromium-51 (400 mCi 10–7 cells, specific activity 200–
500 mCi mg–1) and incubated for 2 h at 37°C. Excess radiolabelled
chromium was removed and labelled tumour cells incubated with
varying numbers of lymphocytes to produce the effector:tumour
cell ratio (E:T). After 4-h incubation, a 70 ml sample of super-
natant was removed for liquid scintillation counting (Canberra-
Packard). Spontaneous release was measured by incubating the
tumour cells in complete media and maximum release determined
by lysing the cells in 0.1 M hydrochloric acid. For all valid assays,
spontaneous release from both treated and untreated tumour cells
was always less than 10% of the maximum release. Blocking
anti-ICAM-1 antibody was used at concentrations ranging from 1
mg ml–1 to 25 mg ml–1, and a non-specific mouse IgG antibody used
as an isotype control. A melanoma-specific antibody (NK1/C3;
TCS Biologicals) which recognizes both intracellular and
cell-surface epitopes was also used as a control antibody, and
had the same effect as the isotype control. Both antibodies were
incubated for 1 h, 37°C with the tumour cells before the addition
of the LAK cells. sICAM-1 was added over a range of concentra-
tions (25 ng ml–1 to 125 ng ml–1) and was present throughout the
lysis assay.
Quantitative analysis of cytotoxicity
The percentage of lysis occurring was calculated as follows: %
specific lysis = (dpm experimental well – dpm spontaneous
release)  ¸ (dpm maximal release – dpm spontaneous release).
Immunofluorescent analysis of mICAM-1
Flow cytometry
Tumour cells were prepared for fluorescent-activated cell sorter
analysis by the addition of 10 ml of FITC-conjugated ICAM-1
antibody (equivalent to one test as described by R&D systems) to
106 tumour cells and incubated for 15 min. Excess antibody was
removed by washing the cells twice in PBS, and fluorescent
staining analysed using a FACscan (Becton Dickinson). Intensity
of fluorescence was recorded on a logarithmic scale, and corre-
sponding background fluorescence intensity obtained using
tumour cells minus antibody was always less than 0.6 units.
Soluble ICAM-1 assay
The procedure for measuring sICAM-1 was as described in the
R&D Systems parameter handbook. Briefly, 100 ml of anti-ICAM-
1 horseradish peroxidase conjugate was added to each well which
had been coated with a murine antibody to human ICAM-1. This
was followed by the addition of diluted supernatant from cells
pretreated with RA (10–10 M to 10–6 M) for 7 days. The plate was
incubated for 2 h at room temperature before the contents of each
well were removed. Wells were washed 6 times with 300 ml of
wash buffer, after which 100 ml of substrate was added to each
well and left to incubate at room temperature for 30 min. One
hundred microlitres of the stop solution was added to each well
and the optical density of the plate read in a microtitre plate reader
set at 450 nm with correction of 620 nm.
Statistical analysis of data
Data were analysed statistically using the two-tailed Student’s 
t-test and values expressed as the average ± s.e.m. of ten separate
samples from a single experiment with the exception of the
sICAM-1 lysis experiments which were performed in triplicate.
RESULTS
Cytotoxicity assay
Unactivated PBL failed to induce lysis of both untreated/treated
C8161 cells and Hs294T cells at all E:T ratios tested (data not
shown). Pretreatment of the C8161 cells for 4 days using the lower
concentrations of RA (10–10 M to 10–8 M) had no significant effect
on LAK cell-mediated tumour cell lysis (Figure 1). Nevertheless,
pretreatment with 10–7 M RA increased lysis of the C8161 cells
1.8-fold (P < 0.05) at the 20:1 ratio, and 1.4-fold (P < 0.05) at the
40:1 ratio (Figure 1). Pretreatment of the C8161 cells with 10–6 M
RA induced a 2-fold increase in lysis at the 20:1 ratio (P < 0.05)
(Figure 1) with similar increases of 1.7-fold (P < 0.05) and1496 CL Alexander et al
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1.6-fold (P < 0.05) at the 40:1 and 80:1 ratios respectively
(Figure 1).
Using the Hs294T cells, 4 days pretreatment with 10–10 M to
10–8 M RA failed to significantly alter tumour cell lysis (Figure 2).
In contrast, pretreatment of the Hs294T cells with 10–7 M and
10–6 M RA significantly increased lysis 1.6-fold (P < 0.05) and 
2-fold (P < 0.05) respectively at the 20:1 E:T ratio (Figure 2).
Similar values were obtained at the 40:1 ratio where lysis was
increased 1.4-fold (P < 0.05) and 2-fold (P < 0.005) using
10–7 M and 10–6 RA respectively (Figure 2).
Pretreatment of the tumour cells for 4 days with 10–5 M RA was
also examined but viability measurements (using trypan blue
staining) revealed a significant decrease in viability of both cell
lines using this concentration of drug. Therefore, for all further
lysis experiments, 10–6 M RA was chosen as this induced the
optimum increase in lysis whilst maintaining cell viability.
Flow cytometric analysis
Fluorescent intensity levels representing mICAM-1 expression
over a 7-day period in control C8161 cells ranged from, on
average, 7.6 to 10.4 (Figure 3). Exposure of the C8161 cells over a
7-day period with RA (10–10 M to 10–8 M) did not significantly alter
mICAM-1 expression (with values of average fluorescent intensity
ranging from 8.5 to 10.6). After 1 day treatment of the C8161 cells
with 10–7 M and 10–6 M RA, mICAM-1 expression was not altered
but levels began to increase 1.4-fold using 10–7 M RA and 1.7-fold
using 10–6 M RA by day 2 (Figure 3). This increase was maintained
with 4 days treatment, where 10–7 M RA induced a 1.3-fold
increase in mICAM-1 expression and a 1.4-fold increase using
10–6 M RA (Figure 3).
Expression of mICAM-1 in control Hs294T cells was on
average 2-fold higher than in the C8161 cells. Pretreatment of the
Hs294T cells over a 7-day period with 10–10 M to 10–9 M RA had
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Figure 1 IL-2-activated PBL lysis of C8161 cells (n n) and C8161 cells
pretreated with 10–10 M RA (n); 10–9 M RA (l l); 10–8 M RA (•); 10–7 M RA (u u)
and 10–6 M RA (u)
Figure 3 Flow cytometric analysis of mICAM-1 expression in C8161 cells
(n n) and C8161 cells pretreated with 10–10 M RA (n); 10–9 M RA (l l); 10–8 M RA
(•); 10–7 M RA (u u) and 10–6 M RA (u)
Figure 2 IL-2-activated PBL lysis of Hs294T cells (n n) and Hs294T cells
pretreated with 10–10 M RA (n); 10–9 M RA (l l); 10–8 M RA (•); 10–7 M RA (u u)
and 10–6 M RA (u)
Figure 4 Flow cytometric analysis of mICAM-1 expression in Hs294T cells
(n n) and C8161 cells pretreated with 10–10 M RA (n); 10–9 M RA (l l); 10–8 M RA
(•); 10–7 M RA (u u) and 10–6 M RA (u)no effect on mICAM-1 expression. However, using 10–8 M RA,
ICAM-1 expression was marginally increased from 19 to 23
fluorescent intensity units on day 3, which was similar by day 4
and day 7 (Figure 4). After 2 days treatment with 10–7 M RA and
10–6 M RA, mICAM-1 expression was increased by both treat-
ments 1.3-fold, remaining at this level by 4 days with
10–7 M RA pretreatment and increasing 1.4-fold with 10–6 M RA
(Figure 4).
Addition of blocking ICAM-1 antibody to the
cytotoxicity assay
Due to the variation in LAK cell populations between individuals,
a lysis assay was set up using the same population of lymphocytes
as used in the blocking assays, to examine the effect of 4 days
pretreatment with 10–6 M RA on lysis of the tumour cells. Then,
10–6 M RA-treated C8161 and Hs294T cells incubated with LAK
cells for a period of 4 h were found to become more susceptible to
lysis than untreated control cells. In the C8161 cell line (Figure 5),
lysis was increased 3.3-fold from 3.5% to 11.5% at the 20:1 ratio
(P < 0.05) with similar increases of 2.8-fold (P < 0.005) and
2.1-fold (P < 0.005) at the 40:1 and 80:1 ratios respectively. A
similar pattern was observed using the Hs294T cell line (Figure 5)
where lysis was increased 3.7-fold at the 5:1 ratio from 13.1%
to 48.4% (P < 0.005), from 39.5% to 55.5% at the 20:1 ratio
(1.4-fold) and from 54.9% to 76.1% at the 40:1 ratio (1.4-fold)
with P-values < 0.05.
Blocking ICAM-1 antibody was added to the cytotoxicity assay
at the 40:1 ratio to untreated tumour cells and to tumour cells that
had been exposed to 10–6 M RA for 4 days. For all comparisons,
lysis on addition of blocking ICAM-1 antibody was compared to a
non-specific IgG control antibody, while use of a melanoma cell-
specific control antibody had no effect. A control of untreated
tumour cells was run with each experiment to show the increase in
lysis induced by RA was consistent with each experiment despite
the slight differences in lysis of the tumour cells using different
populations of LAK cells. Addition of 5 mg ml–1 of anti-ICAM
antibody at the 40:1 ratio (Figure 6A) caused a highly significant
1.5-fold decrease in lysis of control C8161 cells (from 16.2% to
10.7%, P < 0.0005). Optimum inhibition was achieved using
10 mg ml–1 of anti-ICAM-1 antibody which reduced lysis from
19.6% to 8.4% (a 2.3-fold difference, P < 0.0005). This inhibition
was maintained at the higher concentration of antibody.
A similar pattern was also observed in RA-treated cells (Figure
6B) where lysis was reduced at 5 mg ml-1 anti-ICAM-1 antibody
from 43.7% to 20.5% (P < 0.005). Optimum inhibition was also
achieved using 10 mg ml–1 anti-ICAM antibody which induced
a threefold reduction in lysis of the cells from 44.0% to 14.4%
(P < 0.005), which was similar at the higher concentration of
antibody.
In the Hs294T cell line (Figure 7A), it was found that at the 40:1
ratio, blocking anti-ICAM-1 antibody at the optimal concentration
Melanoma ICAM-1 and LAK cell lysis 1497
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Figure 5 IL-2-activated PBL lysis of Hs294T cells pretreated without (n n)
and with (n) 10–6 M RA and lysis of C8161 cells pretreated without (l l) and
with (•) 10–6 M RA. Values are represented as the average ± s.e.m. where
*P < 0.05 and **P < 0.005
Figure 6 (A) Effect of blocking anti-ICAM-1 antibody (cross-hatched bar) on
the lysis of C8161 cells (open bar) at an E:T ratio of 40:1. Non-specific IgG
antibody was also included as a control (hatched bar). Values are
represented as the average ± s.e.m. where *P < 0.0005 and represents
comparison of control IgG with anti-ICAM-1 antibody. (B) Effect of blocking
anti-ICAM-1 antibody (cross-hatched bar) on the lysis of C8161 cells
pretreated for 4 days with 10–6 M RA (solid bar) at an E:T ratio of 40:1. Non-
specific IgG antibody was also included as a control (hatched bar). Values
are represented as the average ± s.e.m. where *P < 0.005 and represents
comparison of control IgG with anti-ICAM-1 antibody1498 CL Alexander et al
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of 5 mg ml–1 significantly reduced lysis of control cells 1.8-fold
from 57.1% to 31.1% (P < 0.001). This reduction was also
observed using 10 mg ml–1 anti-ICAM-1 antibody that reduced
lysis 1.9-fold (P < 0.001). On treatment of Hs294T cells with
10–6 M RA (Figure 7B) lysis was significantly reduced using anti-
ICAM-1 antibody at 5 mg ml–1 which caused a 1.3-fold reduction
in lysis from 67.8% to 53.4% (P < 0.05). Similar reductions were
observed at all other antibody concentrations tested.
ELISA assay for measuring sICAM-1 expression
C8161 cells secreted basal of 43.6 fg ICAM-1 per cell after 2 days,
which was slightly increased to 51.3 fg per cell by day 4, and to
56.5 fg per cell by day 7. Measurements taken over a 7-day period
revealed that RA pretreatment with 10–10 M to 10–6 M RA did not
significantly alter mICAM-1 expression (values ranging from 45.9
to 60.3 fg ICAM-1 per cell on day 2, and 43.6 to 64.9 fg ICAM-1
per cell by day 7).
By day 2, the Hs294T cell line secreted 3.9-fold lower levels of
sICAM-1, which did not change significantly following treatment
with 10–10 M to 10–6 M RA over a 7-day period (values ranging
from 10.4 fg per cell to 14.0 fg per cell on day 2, from 16.4 fg per
cell to 23.9 fg per cell on day 4, and from 15.5 fg per cell to 22.9 fg
per cell by day 7).
Addition of sICAM-1 to the cytotoxicity assay
Addition of sICAM-1 over a range of concentrations (25–
125 ng ml–1) to control C8161 cells did not alter their suscepti-
bility, but RA treatment of cells in combination with sICAM-1
addition, significantly reduced lysis in a dose-dependent manner
with lysis decreasing from 50.2% to 38% using 75 ng ml–1
(P < 0.05), and was further reduced to 24.9% (P < 0.0005) using
the highest concentration of sICAM-1 (125 ng ml–1) (Figure 8).
In contrast, addition of sICAM-1 at the 40:1 ratio, using control
or RA-treated Hs294T did not alter tumour cell lysis (data not
shown).
DISCUSSION
Previous investigators have reported on the RA-induced increase
of mICAM-1 expression in various cell types (Bouillon et al,
1991; Wang et al, 1992; Bassi et al, 1995; Babina et al, 1997),
while this study demonstrates a RA-induced increase in
ICAM-1 levels in C8161 and Hs294T human melanoma cell
lines. Increases in ICAM-1 expression by cytokines (Jackson et al,
1992; Cao et al, 1997; Eisenthal et al, 1998) and ICAM-1 gene
transfection (Lefor and Fabian, 1998) have been correlated with
an increased susceptibility of tumour cell lysis. Therefore, we
have subsequently examined the correlation between ICAM-1
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expression and the susceptibility of RA-treated cell lines to lysis
by LAK cells. The data generated from our blocking ICAM-1 anti-
body studies indicate mICAM-1 to be partially involved in the
tumour/PBL interaction of both treated and untreated tumour cells,
providing further evidence for the involvement of ICAM-1 in the
immune response to tumours (Maio et al, 1989; Vanky et al, 1990;
Jackson et al, 1992; Pandolfi et al, 1992). We have demonstrated
that this increase in mICAM-1 expression in response to RA treat-
ment cannot be solely responsible for the increase in LAK cell-
mediated lysis of RA-treated tumour cells, as addition of blocking
ICAM-1 antibody to the cytotoxicity assays does not reduce lysis
to the same level of control experiments. It therefore appears that
RA modulates the expression of other molecules in addition to
ICAM-1 on the tumour cell surface that could ultimately alter the
sensitivity of the tumour cells to LAK cell-mediated lysis. Possible
candidate molecules which are known to be involved in the
tumour/immune response and which may be regulated by RA
include ICAM-2, major histocompatibility complex (MHC) class I
and II and LFA-3 (Kaufman, 1995; Gwin et al, 1996). However,
despite our findings that the tumour cells weakly express MHC
class I molecules, we were unable to show that blocking the
HLA–ABC complex with antibody over a range of concentrations
had any effect on lysis of either cell line (data not shown).
Previous reports indicate mICAM-1 expression in melanoma
correlates with an increased risk of metastasis (Johnson et al,
1989; Kageshita et al, 1993). This somewhat conflicting statement
may be explained by the existence of soluble ICAM-1 that can
interact with LFA-1 on the lymphocyte and block the lymphocyte
from interacting with and lysing the tumour cell. Nude mouse
models have previously shown melanoma cells to be a source of
sICAM-1 (Giavazzi et al, 1992), a finding supported by our
ELISA results which show the C8161 and Hs294T cell lines
secrete sICAM-1. There is evidence to show that patients with
malignant melanoma who have higher levels of sICAM-1 have a
reduced survival rate (Harning et al, 1991). It is interesting to note
that in our melanoma cell lines, the highly metastatic C8161 cells
secrete 4-fold greater levels of sICAM-1 per cell than the poorly
metastatic Hs294T cells which may contribute to the greater
ability of the C8161 cells to metastasize in the experimental
metastasis model (authors’ unpublished observations). No reports
exist as to the effect of RA on sICAM-1 expression but we have
shown levels of secreted ICAM-1 in these two cell lines to be
unaffected by RA treatment. One can speculate from such a result
that the immunological consequences of RA treatment in these cell
lines is not via the induction of sICAM-1 and that the mechanisms
of regulation of mICAM-1 and sICAM-1 are independent of one
another in these cell lines. This has also been observed by
Heymann et al (1995) who reported that the induction of mICAM-
1 by certain cytokines had no effect on sICAM-1 expression. The
mechanisms involved in the release of sICAM-1 are unclear;
however, it is possible that the soluble form arises either by differ-
ential RNA splicing, as is true for P-selectin (Ishiwata et al, 1994),
but no corresponding mRNA has been observed, or it may arise
via enzymatic cleavage of membrane-associated ICAM-1 to form
sICAM-1. Proteolytic cleavage appears to be the most likely
explanation and has been suggested in an earlier report by Jackson
et al (1993) who observed the shedding of sICAM-1 from bladder
cancer cells in response to IFN-g which was accompanied by
downregulation of mICAM-1 expression. In a more recent study
by Budnik et al (1996) it was shown that the addition of protease
inhibitors to keratinocytes had the ability to inhibit production of
sICAM-1 supporting a model of proteolytic cleavage in the release
of ICAM-1. If proteolytic cleavage is indeed the mechanism for
sICAM-1 production, then our data suggests that RA is unable to
affect the putative protease(s) required to cleave the membrane
form of ICAM-1.
sICAM-1 has been shown to bind to LFA-1 on the LAK cell
surface which would ultimately prevent the lymphocytes from
interacting with mICAM-1, preventing lysis of the tumour cell.
Altomonte et al (1993) reported on the inhibition of melanoma cell
lysis by sICAM, whereas Sanchez-Rovira et al (1998) have shown
an inhibition of colorectal cancer cell lysis using sICAM-1.
However, in contrast to this, we demonstrate that introduction of
this soluble form to the lysis assay of both the Hs294T cells and
the C8161 cells does not alter lysis, an observation supported by
recent data from Young et al (1997), who found that addition of
sICAM to the cytotoxicity assays of bladder cancer cell lines had
no effect on lysis. Our data indicates sICAM-1 release from these
melanoma cells appears to be unimportant in the evasion of the
melanoma cells from the immune system in vitro. However, it
does not rule out the possibility that in the in vivo situation,
sICAM may exist bound to other proteins or as a multimeric form
which may have a greater potential to bind to LFA-1 sites on the
lymphocyte which could contribute to tumour cell evasion. In
contrast to this, sICAM-1 addition to RA-treated C8161 cells
reduced lysis, suggesting sICAM-1 interference of the tumour/
LAK cell interaction plays a significant role in preventing lysis of
RA-treated tumour cells. It appears that the combination of
sICAM-1 and the RA-induced alterations in membrane molecules
is sufficient to partially prevent lysis of the highly metastatic cells.
In summary, we have demonstrated that RA treatment of C8161
and Hs294T human melanoma cell lines induces these cells to
become more susceptible to lysis by LAK cells, and although
ICAM-1 is involved in this LAK/tumour cell interaction, the
observed RA-induced increase in mICAM-1 expression cannot
solely account for the increase in lysis with RA treatment. We
have shown sICAM-1 to be secreted by both cell lines, and to be
expressed in larger amounts in the highly metastatic cell line
compared to the poorly metastatic tumour cells. Addition of
sICAM-1 to the assay has no effect on lysis of the tumour cells but
reduces lysis of the highly metastatic RA-treated C8161 cells.
Further work will be required to define changes in surface
expression of other molecules involved in the LAK/tumour cell
response in combination with our current studies analysing the
distribution of RA receptors (RAR) in these cell lines to determine
whether a relationship exists between RA sensitivity, RAR expres-
sion and ICAM-1 expression.
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